Drug Approval | September 01, 2022
Biological E. announces CDSCO recommendation of its infant’s vaccine
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
The unit has filed 2 Derma products and 1 MDI product.
Indonesia national agency for drug and food control, BPOM, approved QDENGA for use in individuals 6 to 45 years of age
Glenmark continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest.
Desvenlafaxine Extended-Release Tablets, 25 mg is a generic equivalent of Pristiq Extended-Release Tablets, 25 mg of PF PRISM C.V.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
Phase 2 Study of MK-2060 Currently Ongoing in People with End-Stage Renal Disease Receiving Hemodialysis
The company continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Subscribe To Our Newsletter & Stay Updated
